Key Takeaways
-
Influenza A Market size projection: As per DelveInsight’s analysis, the total market size of Influenza A infections in the 7MM is expected to surge significantly by 2034, with the United States accounting for the largest market size compared to EU4, UK, and Japan in 2024.
-
Influenza A Patient population data: The report provides the total Influenza A potential pool segmented by total vaccinated pool of influenza A, total influenza vaccine failure cases, total influenza A positive cases, and strain-specific cases of influenza A across the 7MM from 2020 to 2034.
-
Key Influenza A companies: Leading Influenza A treatment companies, such as Roche, BioCryst Pharmaceuticals, Seqirus, Moderna, Cidara Therapeutics, GlaxoSmithKline, Cocrystal Pharma, and others, are actively developing innovative therapeutic solutions.
-
Influenza A Pipeline assets: Some of the key Influenza A therapies in the pipeline include mRNA-1010 (Moderna), CD388 (Cidara Therapeutics), Flu Pandemic mRNA GSK4382276A (GlaxoSmithKline), CC-42344 (Cocrystal Pharma), and others targeting various mechanisms of action.
-
Recent developments:
-
In March 2025, Cidara Therapeutics announced two upcoming presentations on CD388 at the 38th International Conference on Antiviral Research.
-
In March 2025, the FDA issued its annual strain-selection recommendations for trivalent seasonal influenza vaccines for the 2025–2026 U.S. season, updating both A(H1N1)pdm09 and A(H3N2) components to match circulating influenza A viruses.
-
In March 2025, the FDA approved Fluad, the first seasonal influenza vaccine containing the MF59 oil-in-water adjuvant, for the prevention of influenza in adults aged ≥65 years.
-
In March 2025, the FDA broadened the indication for Flublok, a recombinant hemagglutinin (HA) influenza vaccine, from adults aged ≥18 years to include children as young as 9 years.
-
In March 2025, Osivax closed the first tranche of its Series B financing, raising €10 million, led by Meiji Seika Pharma, to advance OVX836, a broad-spectrum influenza vaccine candidate.
-
In January 2025, Roche filed regulatory submissions in Europe for XOFLUZA for pediatric patients aged 0 to 1 year
-
In September 2024, Roche announced positive topline results of the Phase III CENTERSTONE study of XOFLUZA showing reduction in influenza virus transmission.
-
Discover more recent advancements in the Influenza A landscape @ Influenza A Recent Developments.
Influenza A Market Dynamics
The influenza A infections market represents a critical segment of the global infectious disease therapeutics landscape, driven by the continuous evolution of viral strains and the urgent need for effective antiviral treatments and prophylactic measures. According to DelveInsight’s Influenza A Infections – Market Insight, Epidemiology And Market Forecast report, the current influenza A market is characterized by established antiviral therapies and a robust pipeline of innovative treatments targeting various mechanisms of viral replication and prevention.
The influenza A Market momentum is primarily fueled by the persistent threat of seasonal and pandemic influenza outbreaks, with influenza A viruses being the only influenza viruses known to cause flu pandemics. The market evolution is significantly influenced by the virus’s ability to spread efficiently among people and against which populations have little or no immunity. Current subtypes of influenza A viruses that routinely circulate in people include A(H1N1) and A(H3N2), creating ongoing demand for updated therapeutic interventions and vaccines.
The scientific rationale driving current market development centers around multiple therapeutic approaches, including neuraminidase inhibitors, polymerase inhibitors, and next-generation vaccine technologies. Established treatments like XOFLUZA (baloxavir marboxil) represent the first-in-class cap-dependent endonuclease protein inhibitors essential for viral replication, while RAPIVAB (peramivir) functions as an influenza virus neuraminidase inhibitor. The emergence of novel mechanisms, such as PB2 inhibitors and Drug-Fc conjugates, represents significant therapeutic advances.
The influenza A clinical development activity demonstrates robust pipeline engagement across multiple phases, with promising candidates advancing through Phase III, Phase II, and Phase I/II trials. The competitive landscape features both established pharmaceutical giants and innovative biotechnology companies, each pursuing distinct strategic approaches to address unmet medical needs in influenza A treatment and prevention.
Current influenza A market challenges include vaccine failure rates, with the US estimated to have around 70% vaccine failure rate in 2024, and the constant antigenic drift and shift of influenza viruses that complicate treatment and prevention strategies. Market opportunities are expanding through the development of universal influenza coverage approaches, long-acting prophylactic treatments, and improved diagnostic capabilities that enable rapid viral identification and subtype determination.
Future outlook indicates substantial growth potential driven by emerging therapies expected to launch during the study period, addressing current unmet needs and contributing to overall market expansion. The expected launch of investigational candidates from companies like Moderna, Cidara Therapeutics, and Cocrystal Pharma is anticipated to significantly impact the influenza A treatment paradigm and drive market growth through 2034.
Download the Influenza A Market report to understand which factors are driving the therapeutic market @ Influenza A Market Trends.
Influenza A Epidemiology
The influenza A epidemiological landscape across the 7MM reveals complex patterns of disease burden and vaccination coverage that directly impact market dynamics and therapeutic development priorities. DelveInsight’s comprehensive epidemiological analysis encompasses the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan, providing detailed segmentation of patient populations from 2020 to 2034.
The total vaccinated pool of influenza A is systematically categorized into distinct age groups, including children aged 0–4 and 5–12, adolescents aged 13-17, adults aged 18–49 and 50–64, individuals ≥65, and pregnant women. Epidemiological data indicates that most vaccinations in the total vaccinated pool were reported in adults aged 18–49 in the US, while the least number of vaccinations were reported in the pregnant women category in 2024. This demographic distribution highlights specific population segments that may require targeted therapeutic interventions and enhanced vaccination strategies.
Geographic segmentation reveals significant regional variations in disease burden and healthcare responses. Among the 7MM countries, the United States maintains the highest market presence, while Spain demonstrates the lowest market size for influenza A in 2024. Within the EU4 and UK region, Germany accounts for the highest market size, reflecting both population demographics and healthcare infrastructure capabilities. According to the Ministry of Health, Labor, and Welfare of Japan, the average number of influenza A cases in 2024 was 64.39 per institution, significantly exceeding the previous peak of 57.09 cases recorded in January 2019.
Strain-specific epidemiological patterns provide crucial insights for therapeutic development and market forecasting. European Respiratory Virus Surveillance Summary (ERVISS) data from 2025 indicates that influenza A (H1N1) pdm09 represents the predominant subtype among all studies, accounting for 57% to 93% of influenza A subtypes in Europe during 2024. This strain dominance influences both vaccine composition decisions and antiviral development priorities, as therapeutic efficacy must address the most prevalent circulating viral variants.
The forecast period extending from 2025 to 2034 projects continued growth in total influenza A positive cases across the 7MM, with particular emphasis on the United States market expansion. These epidemiological projections directly correlate with market growth expectations and provide the foundation for pharmaceutical companies to assess addressable patient populations and develop appropriate commercial strategies for emerging therapeutic interventions.
Discover evolving trends in the Influenza A epidemiology forecasts @ Influenza A Patient Pool Analysis.
Key Influenza A Companies and Treatment Market Context
The influenza A treatment landscape encompasses a diverse array of established and emerging therapeutic approaches, with key market participants pursuing innovative strategies to address the complex challenges of viral respiratory disease management. The current clinical and regulatory environment features approved antiviral medications that play vital roles in managing influenza infections by treating the disease and reducing the risk of serious complications such as bacterial pneumonia and sepsis.
Established influenza A treatment options include four FDA-recommended antiviral drugs: TAMIFLU, RELENZA, RAPIVAB, and XOFLUZA, with TAMIFLU and RELENZA receiving initial FDA approval in 1999, followed by newer therapeutic options introduced after nearly fifteen years. XOFLUZA (baloxavir marboxil), developed by Roche, represents a breakthrough as the first cap-dependent endonuclease protein inhibitor, receiving FDA approval in October 2018 for treating acute, uncomplicated influenza in patients 12 years and older, with subsequent pediatric approvals expanding its clinical utility.
The influenza A clinical pipeline activity demonstrates robust development across multiple phases and therapeutic approaches. Key players include Roche (XOFLUZA), BioCryst Pharmaceuticals (RAPIVAB), Seqirus (FLUAD QUADRIVALENT), Moderna (mRNA-1010), Cidara Therapeutics (CD388), GlaxoSmithKline (Flu Pandemic mRNA GSK4382276A), and Cocrystal Pharma (CC-42344). Each company brings distinct therapeutic mechanisms and development strategies to address various aspects of influenza A prevention and treatment.
Moderna’s mRNA-1010 represents next-generation vaccine technology currently advancing through Phase III clinical trials for seasonal influenza prevention. Cidara Therapeutics’ CD388 employs innovative Drug-Fc conjugate technology designed to achieve universal prevention of seasonal and pandemic influenza with single-dose administration, having received FDA Fast Track designation in June 2023. The company initiated the Phase IIb NAVIGATE study in September 2024 to further evaluate efficacy and safety in influenza prevention.
Development milestones continue to shape the competitive landscape, with Cocrystal Pharma’s CC-42344 demonstrating novel PB2 inhibitor mechanisms against influenza A strains, including avian pandemic strains and resistant variants. The company completed enrollment of 78 subjects in its randomized, double-blind, placebo-controlled Phase IIa human challenge clinical study in May 2024. Commercial arrangements include significant partnerships, such as Cidara’s license and technology transfer agreement with Janssen in April 2024, reacquiring all rights for CD388 development and commercialization, and BioCryst’s September 2024 HHS contract award of up to $69 million for RAPIVAB procurement over a five-year period.
Delve deeper into the major and specialised companies in the Influenza A market @ Influenza A Competitive Landscape.
Conclusion
The influenza A infections market represents a dynamic and expanding therapeutic area poised for significant growth through 2034, driven by innovative treatment approaches, emerging pipeline therapies, and evolving epidemiological patterns across the 7MM. With established antiviral treatments providing the current foundation and promising investigational candidates advancing through clinical development, the market is positioned to address persistent unmet medical needs while capitalizing on technological advances in vaccine development, antiviral mechanisms, and prophylactic strategies. The convergence of robust clinical pipelines, regulatory support through designations like Fast Track status, and substantial commercial investments underscores the market’s potential for sustained expansion and improved patient outcomes in influenza A management.
Scope of the Influenza A Market Report
-
The report covers a segment of key events, an executive summary, and a descriptive overview of influenza A, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies
-
A detailed review of the influenza A market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach, covering the 7MM drug outreach
-
The influenza A report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM influenza A market
-
The influenza A patient Population analysis and segmentation
-
Influenza A Pipeline Analysis covering therapeutic approaches and development phases
-
Therapeutic Approaches evaluation and clinical development assessment
-
Influenza A Market Size and Trends analysis with historical and forecasted data
-
Existing and Future Market Opportunity identification and assessment
-
Ten Years Forecast period covering 2025-2034 market projections
-
The 7MM Coverage including United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan
-
Influenza A Epidemiology Segmentation including total vaccinated pool, vaccine failure cases, positive cases, and strain-specific cases
-
Key Cross Competition analysis and competitive landscape assessment
-
Influenza A Drugs Uptake and Key Market Forecast Assumptions for emerging and approved therapies
-
Current Treatment Practices evaluation and clinical guideline analysis
-
Influenza A market unmet needs identification and market gap analysis
-
Influenza A Pipeline Product Profiles with detailed therapeutic candidate assessments
-
Market Attractiveness analysis and investment opportunity evaluation
-
Qualitative Analysis including SWOT Analysis and Conjoint Analysis for strategic insights
Table of Contents
1. Key Insights
2. Executive Summary of Influenza A
3. Competitive Intelligence Analysis for Influenza A
4. Influenza A Market Overview at a Glance
5. Influenza A: Disease Background and Overview
6. Influenza A Patient Journey
7. Influenza A Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Influenza A Unmet Needs
10. Key Endpoints of Influenza A Treatment
11. Influenza A Marketed Products
12. Influenza A Emerging Therapies
13. Influenza A: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Influenza A
17. KOL Views
18. Influenza A Market Drivers
19. Influenza A Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services